AR119673A1 - Compuestos bicíclicos de cetona y métodos para utilizarlos - Google Patents
Compuestos bicíclicos de cetona y métodos para utilizarlosInfo
- Publication number
- AR119673A1 AR119673A1 ARP200100056A ARP200100056A AR119673A1 AR 119673 A1 AR119673 A1 AR 119673A1 AR P200100056 A ARP200100056 A AR P200100056A AR P200100056 A ARP200100056 A AR P200100056A AR 119673 A1 AR119673 A1 AR 119673A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- pyrrolo
- dihydro
- triazol
- fluoro
- Prior art date
Links
- -1 KETONE COMPOUNDS Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- CLELLYLGVVWSNC-UHFFFAOYSA-N (2,2-dimethyl-3-oxabicyclo[3.1.0]hexan-1-yl)-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound CC1(C)OCC(C2)C12C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O CLELLYLGVVWSNC-UHFFFAOYSA-N 0.000 abstract 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- FBORMSYFVQSNPV-UHFFFAOYSA-N 1-[7-fluoro-5-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-one Chemical compound CCC(=O)C1=NN2C(CC(C2=N1)F)C3=CN(N=C3)C FBORMSYFVQSNPV-UHFFFAOYSA-N 0.000 abstract 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 abstract 1
- UBGABCPJLOUPOD-UHFFFAOYSA-N CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O UBGABCPJLOUPOD-UHFFFAOYSA-N 0.000 abstract 1
- ZQVFZBINUZNLET-UHFFFAOYSA-N CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O ZQVFZBINUZNLET-UHFFFAOYSA-N 0.000 abstract 1
- MSWPUSCLYLQSOD-KBPBESRZSA-N CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O Chemical compound CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O MSWPUSCLYLQSOD-KBPBESRZSA-N 0.000 abstract 1
- RYFGSKWVGYBXNB-UHFFFAOYSA-N N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 Chemical compound N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 RYFGSKWVGYBXNB-UHFFFAOYSA-N 0.000 abstract 1
- UCBCDYATPTZCCC-UHFFFAOYSA-N [5-(3-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-cyclopropylmethanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CC=C4)Cl UCBCDYATPTZCCC-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- ADJGHHDLGNZOCP-UHFFFAOYSA-N cyclopropyl-(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound C1CC1C(=O)C2=NN3CCC(C3=N2)C4=CC=CC=C4 ADJGHHDLGNZOCP-UHFFFAOYSA-N 0.000 abstract 1
- HXHYIBLISMREFM-GHMZBOCLSA-N cyclopropyl-[(5R,7R)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@H](C[C@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-GHMZBOCLSA-N 0.000 abstract 1
- HXHYIBLISMREFM-QWRGUYRKSA-N cyclopropyl-[(5S,7S)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@@H](C[C@@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-QWRGUYRKSA-N 0.000 abstract 1
- HXHYIBLISMREFM-UHFFFAOYSA-N cyclopropyl-[7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791118P | 2019-01-11 | 2019-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119673A1 true AR119673A1 (es) | 2022-01-05 |
Family
ID=69528972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100056A AR119673A1 (es) | 2019-01-11 | 2020-01-09 | Compuestos bicíclicos de cetona y métodos para utilizarlos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12344612B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908586B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7585205B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113302193B (cg-RX-API-DMAC7.html) |
| AR (1) | AR119673A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202043229A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020146615A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3214802A1 (en) * | 2021-04-02 | 2022-10-06 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| WO2023225041A1 (en) | 2022-05-19 | 2023-11-23 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| PL382706A1 (pl) | 2002-08-26 | 2007-11-26 | Takeda Pharmaceutical Company Limited | Związek modulujący receptor wapnia i jego zastosowanie |
| JP4995423B2 (ja) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換ジピリジルアミン類及びそれらの使用 |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
| TWI710558B (zh) | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| AU2014287471C1 (en) | 2013-07-10 | 2019-11-28 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三環式dlk阻害剤及びその使用 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AU2017356887B2 (en) | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN119613408A (zh) * | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| WO2019072942A1 (en) | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
-
2020
- 2020-01-09 CN CN202080008933.9A patent/CN113302193B/zh active Active
- 2020-01-09 EP EP20704652.5A patent/EP3908586B1/en active Active
- 2020-01-09 WO PCT/US2020/012908 patent/WO2020146615A1/en not_active Ceased
- 2020-01-09 TW TW109100698A patent/TW202043229A/zh unknown
- 2020-01-09 JP JP2021539523A patent/JP7585205B2/ja active Active
- 2020-01-09 AR ARP200100056A patent/AR119673A1/es unknown
-
2021
- 2021-07-08 US US17/371,001 patent/US12344612B2/en active Active
-
2025
- 2025-05-23 US US19/217,418 patent/US20250282788A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210340151A1 (en) | 2021-11-04 |
| CN113302193B (zh) | 2026-05-29 |
| TW202043229A (zh) | 2020-12-01 |
| EP3908586A1 (en) | 2021-11-17 |
| JP2022516651A (ja) | 2022-03-01 |
| US20250282788A1 (en) | 2025-09-11 |
| JP7585205B2 (ja) | 2024-11-18 |
| US12344612B2 (en) | 2025-07-01 |
| EP3908586B1 (en) | 2022-12-21 |
| WO2020146615A1 (en) | 2020-07-16 |
| CN113302193A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161388A1 (es) | Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| JP2020515575A5 (cg-RX-API-DMAC7.html) | ||
| AR097388A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
| PE20180530A1 (es) | Derivados de amidas policiclicas como inhibidores de cdk9 | |
| AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| JP2016519156A5 (cg-RX-API-DMAC7.html) | ||
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| RU2019119899A (ru) | Новое дизамещенное 1,2,4-триазиновое соединение | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| AR055074A1 (es) | Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas. | |
| JP2020515620A5 (cg-RX-API-DMAC7.html) | ||
| AR111251A1 (es) | Herbicidas de piridazinona | |
| RU2016117732A (ru) | Антагонисты рецептора соматостатина подтипа 5 (sstr5) | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
| AR100776A1 (es) | Compuestos herbicidas | |
| BR112016005994A2 (pt) | derivados de etinila | |
| AR100360A1 (es) | Derivados de la quinazolindiona farmacológicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |